Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mitochondrial electron transport chain (ETC) and mitochondrial reactive oxygen species (mROS) pools constitute the central bioenergetic and redox signaling hub of the eukaryotic cell (1.5.1, 1.5.4). Located within the inner mitochondrial membrane, the ETC comprises four multi-subunit enzyme complexes (I-IV) and two mobile electron carriers (ubiquinone and cytochrome c) that facilitate the transfer of electrons to molecular oxygen (1.1.3, 1.5.2). This process generates a proton-motive force used by ATP synthase (Complex V) to produce ATP, while simultaneously producing mROS as a byproduct of electron leakage, primarily at Complexes I and III (1.1.2, 1.2.2). At physiological levels, mROS function as critical signaling molecules for metabolic adaptation and immune responses, but their dysregulation leads to oxidative stress, mitochondrial DNA damage, and the initiation of apoptotic pathways (1.2.1, 1.4.4). Pharmacological modulation of this system is a key strategy in treating metabolic, oncological, and neurodegenerative disorders (1.1.1, 1.3.2). For example, the biguanide metformin exerts its therapeutic effects in diabetes and potentially cancer through the partial inhibition of Complex I, which reduces hepatic gluconeogenesis and modulates cellular energy sensing (1.1.4, 1.3.4). In oncology, mitocans are developed to selectively disrupt the ETC in malignant cells, leveraging their altered metabolic state to trigger lethal ROS bursts (1.1.1, 1.1.2). Conversely, in conditions characterized by mitochondrial decay, such as Parkinson's disease or aging, therapeutic efforts focus on protecting ETC integrity or utilizing mitochondria-targeted antioxidants like MitoQ to neutralize excessive ROS (1.1.3, 1.2.2). However, the essential nature of mitochondrial function across all tissues presents significant safety challenges, including the risk of systemic lactic acidosis and toxicity to high-energy organs like the heart and brain (1.3.1, 1.3.3).
Inhibition of respiratory chain complexes (I-IV), modulation of mitochondrial reactive oxygen species (mROS) production, scavenging of mitochondrial free radicals, and stabilization of the mitochondrial inner membrane to maintain bioenergetic efficiency or induce apoptosis.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial electron transport chain and mitochondrial reactive oxygen species pools (ETC/mROS).